Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Lymphoma 7Lymphoma, Large B-Cell, Diffuse 5Glioblastoma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Graft vs Host Disease 2Glioma 2Carcinoma, Renal Cell 2

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × Vorinostat × Clear all
NCT00910000 2018-09-10

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1/2 Terminated
15 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00976183 2017-04-10

Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Gynecologic Oncology Associates

Phase 1/2 Terminated
18 enrolled 7 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡